Based on 12-month follow-up clinical data from its safety and feasibility study, Intralink-Spine has reported that the company’s Réjuve system has continued to effectively eliminate or reduce low back pain and disability associated with degenerative disc disease.
According to the company website, Réjuve is “an injectable crosslinking device that mechanically strengthens and rapidly stabilises the disc; thereby, reducing the pain of the patient.” It is designed to be injected once in an outpatient basis.
“We continue to be very pleased with the patient outcomes,” states Tom Hedman, the inventor of the system and adjunct associate professor in the F Joseph Halcomb III, Department of Biomedical Engineering at the University of Kentucky, Louisville, USA. “Twelve months after the Réjuve procedure, three of the four (3/4) patients eligible for this follow-up assessment have no (zero) low back pain and no (zero) disability…The fourth patient has minimal pain and disability. These initial clinical results demonstrate a long-lasting, significant reduction or elimination of pain and disability, not just a slight reduction, and these benefits began within days of the initial procedure. We also have objective imaging data demonstrating the elimination of clinical instability.”
